Document Detail

Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII.
MedLine Citation:
PMID:  8737639     Owner:  NLM     Status:  MEDLINE    
In dyslipidemic or hyperlipidemic patients etofibrate (CAS 31637-97-5, active principle of Lipo-Merz-retard) improves plasma lipoprotein profiles by reducing low density lipoprotein cholesterol and triglycerides. Experimentally, it also promotes fibrinolysis and thrombolysis and reduces the susceptibility of lipoproteins to oxidative stress. In order to investigate the possible efficacy of etofibrate on atherosclerosis, a study in African Green Monkeys was performed. To accelerate atherogenesis, balanced groups of adult male Vervetes (Cercopithecus aethiops) were fed an atherogenic diet, with and without etofibrate, while negative controls received a prudent diet. Total dietary risk exposure was 38 months, with etofibrate treatment during the final 27 months. The etofibrate dose achieved plasma concentrations of clofibric acid comparable to the one achieved clinically. Necropsy demonstrated lesions equivalent to human atherosclerosis types I-VII, which were compared between treatments both macroscopically and microscopically. Peripheral atherosclerosis was significantly less frequent after etofibrate treatment than in positive controls. In aortas, etofibrate probably ameliorated atherogenesis, as defined by proliferation of smooth muscle and foam cells, and accumulation of cholesterol crystals. Effective reduction of plasma cholesterol by etofibrate was confirmed. In conclusion, anti-atherogenic efficacy of etofibrate was demonstrated in a non-human primate model of accelerated atherogenesis. The results on peripheral atherosclerosis confirm the preliminary clinical data in patients suffering from peripheral vascular occlusion.
J E Fincham; G Quack; P Wülfroth; A J Benadé
Related Documents :
6840299 - Metabolic changes in the arterial wall associated with atherosclerosis in the pigeon.
6770479 - Artery stenosis inhibits regression of diet-induced atherosclerosis.
12628029 - Dietary cholesterol reduces lipoprotein lipase activity in the atherosclerosis-suscepti...
3294229 - Brief overview of the mounting evidence that atherosclerosis is both preventable and re...
12492629 - Effect of palm olein oil in a moderate-fat diet on plasma lipoprotein profile and aorti...
3671659 - Cholesterol and dominance rank in the cayo santiago macaques.
173479 - Enzymatic determinations of cholesterol in high-density-lipoprotein fractions prepared ...
6526399 - Unsuspected caffeine toxicity complicating theophylline therapy.
1493139 - Effect of casein, casein phosphopeptides and calcium intake on ileal 45ca disappearance...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Arzneimittel-Forschung     Volume:  46     ISSN:  0004-4172     ISO Abbreviation:  Arzneimittelforschung     Publication Date:  1996 May 
Date Detail:
Created Date:  1996-11-08     Completed Date:  1996-11-08     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0372660     Medline TA:  Arzneimittelforschung     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  519-25     Citation Subset:  IM    
National Research Programme for Nutritional Intervention, Medical Research Council, Tygerberg, South Africa.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antilipemic Agents / adverse effects,  therapeutic use*
Aorta, Thoracic / pathology
Arteriosclerosis / drug therapy*,  pathology
Body Weight / physiology
Cercopithecus aethiops
Clofibric Acid / adverse effects,  analogs & derivatives*,  therapeutic use
Coronary Vessels / pathology
Diet, Atherogenic
Eating / drug effects
Lipids / blood
Lipoproteins / blood
Organ Size / physiology
Reg. No./Substance:
0/Antilipemic Agents; 0/Lipids; 0/Lipoproteins; 31637-97-5/etofibrate; 882-09-7/Clofibric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of acetylsalicylic acid, paracetamol and caffeine and a combination of these substances on k...
Next Document:  Studies of the K(ATP) channel opening activity of the new dihydropyridine compound 9-(3-cyanophenyl)...